Literature DB >> 12424411

TORCH agents in pregnant Saudi women.

Hani O Ghazi1, Abdulwahab M Telmesani, Mahomed F Mahomed.   

Abstract

OBJECTIVE: To determine the seroprevalence rates of IgG to common TORCH agents in pregnant Saudi women using indirect enzyme-linked immunosorbent assay. SUBJECTS AND METHODS: A total of 926 samples of sera were tested for antibodies to TORCH agents known to cause serious congenital infections: Toxoplasma gondii, rubella, cytomegalovirus (CMV), herpes simplex viruses (HSV-1 and HSV-2), varicella zoster virus (VZV) and human immunodeficiency virus (HIV-1 and HIV-2).
RESULTS: Toxoplasma IgG antibodies were detected in 35.6%, CMV total IgG antibodies were found in 92.1%, rubella IgG antibodies in 93.3%, HSV-1 IgG antibodies in 90.9%, HSV-2 IgG in 27.1%, and VZV IgG antibodies in 74.4%. A 0% seroprevalence rate for HIV-1 and -2 was found.
CONCLUSION: Pregnant Saudi women commonly have IgG antibodies to rubella, CMV, HSV-1 and -2, VZV, and T. gondii. Serological evidence of HIV infection was not observed. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424411     DOI: 10.1159/000065813

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  23 in total

1.  Evaluation of the HerpeSelect Express rapid test in the detection of herpes simplex virus type 2 antibodies in patients with genital ulcer disease.

Authors:  Hani Al-Shobaili; Khaled M Hassanein; Marwa Salah Mostafa; Ali Saleh Al Duways
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

2.  High seropositivity of IgG and IgM antibodies against cytomegalovirus (CMV) among HIV-1 seropositive patients in Ilorin, Nigeria.

Authors:  Adeola Fowotade; Iheanyi Omezuruike Okonko; Olajide Olubunmi Agbede; S T Suleiman
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

Review 3.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

4.  Seroprevalence and risk factors of Toxoplasma gondii infection among pregnant women in south western, Saudi Arabia.

Authors:  Mona A Almushait; Saad M Bin Dajem; Nahla M Elsherbiny; Mamdoh A Eskandar; Tarik A Al Azraqi; Laila M Makhlouf
Journal:  J Parasit Dis       Date:  2012-11-02

Review 5.  Epidemiology and factors influencing varicella infections in tropical countries including Sri Lanka.

Authors:  S W P Lakmini Daulagala; Faseeha Noordeen
Journal:  Virusdisease       Date:  2018-07-06

6.  Seropositivity and determinants of immunoglobulin-G (IgG) antibodies against Herpes simplex virus (HSV) types -1 and -2 in pregnant women in Port Harcourt, Nigeria.

Authors:  Iheanyi Omezuruike Okonko; Tochi Ifeoma Cookey
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

Review 7.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

8.  Prevalence of herpes simplex virus types 1 and 2 and associated sociodemographic variables in pregnant women attending king fahd hospital of the university.

Authors:  Obeid E Obeid
Journal:  J Family Community Med       Date:  2007-01

9.  Seroprevalence of Cytomegalovirus among pregnant women and hospitalized children in Palestine.

Authors:  Tahani Neirukh; Ayda Qaisi; Niveen Saleh; Areej Abu Rmaileh; Eman Abu Zahriyeh; Lina Qurei; Firas Dajani; Taghreed Nusseibeh; Hatem Khamash; Sabri Baraghithi; Maysa Azzeh
Journal:  BMC Infect Dis       Date:  2013-11-09       Impact factor: 3.090

10.  The Seroprevalence and Risk Factors of Toxoplasmosis Among Female Undergraduate University Students in Saudi Arabia.

Authors:  Riyadh A Alzaheb; Osama Al-Amer
Journal:  Oman Med J       Date:  2017-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.